KRAS and neoplasm: Secondary KRAS mutations arise and are responsible for acquired resistance in approximately 50% of the patients who initially respond to cetuximab or panitumumab and in fact, mt-KRAS alleles can be detected in patients’ blood using highly sensitive circulating tumor DNA analysis methods before disease progression is clinically manifested [45,46].